Skip to main content

Looking to plant more biotech seedlings, Peninsula genetic disease firm lands $300M

On top of 18 single-molecule subsidiaries, the company looks to add three to five new projects from academic labs or medical centers over the next two years.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.